Description
AMG is currently under investigation and has not been approved for use in colorectal cancer. Its clinical efficacy and safety profile are still being evaluated through ongoing clinical trials.
Mechanism of Action
AMG is an investigational drug and its mechanism of action has not been fully elucidated or approved by the FDA for clinical use in colorectal cancer.
Side Effects
Side effects are not yet fully known as AMG is still under investigation; however
Common side effects may include fatigue
Nausea
And hematological abnormalities.
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT07094113
Phase 1
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
United States, Australia, Belgium, Canada, China, Denmark, France, Germany, Ital
NCT06131398
Phase 1
Active, not recruiting
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
United States, Australia, Canada, France, Japan, Netherlands, Poland, South Kore
NCT04185883
Phase 1
Active, not recruiting
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
United States, Australia, Austria, Belgium, Canada, Germany, Italy, Japan, Nethe
NCT02713529
Phase 1
Archived
Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
United States, Australia, Belgium, Canada, Germany, Spain
NCT02437916
Phase 1
Archived
Safety Study of AMG 228 to Treat Solid Tumors
United States, Australia, Belgium, France, Germany
NCT01562899
Phase 1
Archived
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
United States, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom